Evidence map›Paper›PMID 28426902›Full record

ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2017

Hepatic steatosis after pediatric liver transplant.

Emily R Perito, Tabitha Vase, Rageshree Ramachandran, Andrew Phelps, Kuang-Yu Jen, Robert H Lustig, Vickie A Feldstein, Philip Rosenthal

Abstract read
In one paragraph

Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Lifestyle interventions in nonalcoholic fatty liver disease.Nature reviews. Gastroenterology & hepatology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Emily R PeritoDepartments of Pediatrics.
Tabitha VaseSchool of Medicine, University of California, San Francisco, San Francisco, CA.
Rageshree RamachandranPathology.
Andrew PhelpsRadiology and Biomedical Imaging.
Kuang-Yu JenDepartment of Pathology and Laboratory Medicine, University of California, Davis, Davis, CA.
Robert H LustigDepartments of Pediatrics.
Vickie A FeldsteinRadiology and Biomedical Imaging.
Philip RosenthalDepartments of Pediatrics.
Laboratoire d’Imagerie Biomédicale · FRCancer Research And Biostatistics · USUniversity of California, Davis · USUniversity of California, San Francisco · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant RecipientsU01AI100807 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FENG, SANDY · 2012 to 2016
$9.5M
TRAINING PROGRAM IN PEDIATRIC GASTROENTEROLOGY/NUTRITIONT32DK007762 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Bayrer · 1998 to 2026
$7.3M
Metabolic Syndrome after Pediatric Liver Transplant: Causes and ConsequencesK23DK099253 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERITO, EMILY ROTHBAUM · 2014 to 2018
$938k
NCATS NIH HHS UL1 TR000004NIAID NIH HHS U01 AI100807NIDDK NIH HHS K23 DK099253NIDDK NIH HHS P30 DK026743NIDDK NIH HHS T32 DK007762
6 · The paper itself

Abstract

Hepatic steatosis develops after liver transplantation (LT) in 30% of adults, and nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in nontransplanted children. However, posttransplant steatosis has been minimally studied in pediatric LT recipients. We explored the prevalence, persistence, and association with chronic liver damage of hepatic steatosis in these children. In this single-center study of pediatric patients transplanted 1988-2015 (n = 318), 31% of those with any posttransplant biopsy (n = 271) had ≥ 1 biopsy with steatosis. Median time from transplant to first biopsy with steatosis was 0.8 months (interquartile range [IQR], 0.3-6.5 months) and to last biopsy with steatosis was 5.5 months (IQR, 1.0-24.5 months); 85% of patients with steatosis also had for-cause biopsies without steatosis. All available for-cause biopsies were re-evaluated (n = 104). Of 9 biopsies that could be interpreted as nonalcoholic steatohepatitis (NASH)/borderline NASH, with steatosis plus inflammation or ballooning, 8 also had features of cholestasis or rejection. Among 70 patients with surveillance biopsies 3.6-20.0 years after transplant, only 1 overweight adolescent had a biopsy with NAFLD (grade 1 steatosis, mild inflammation, no ballooning or fibrosis)-despite a 30% prevalence of overweight/obesity in the cohort and 27% with steatosis on previous for-cause biopsy. Steatosis on preceding for-cause biopsy was not associated with portal (P = 0.49) or perivenular fibrosis (P = 0.85) on surveillance biopsy. Hepatic steatosis commonly develops early after transplant in children and adolescents, but it rarely persists. Biopsies that did have steatosis with NASH characteristics were all for-cause, mostly in patients with NAFLD risk factors and/or confounding causes of liver damage. Prospective studies that follow children into adulthood will be needed to evaluate if and when hepatic steatosis presents a longterm risk for pediatric LT recipients. Liver Transplantation 23 957-967 2017 AASLD.

Indexed as

AdolescentBiopsyChildFatty LiverFemaleHumansLiver TransplantationMalePostoperative ComplicationsProspective Studies

Identifiers

PMID28426902
PMCPMC5604881
OpenAlexW2606793983

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.